Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
three
months ended in Sep. 2023,
PHAXIAM Therapeutics paid€0.00 Mil more to buy back shares than it received from issuing new shares.
It received€0.00 Mil from issuing more debt.
It paid€0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
It received€0.00 Mil from paying cash dividends to shareholders.
It received€0.00 Mil on other financial activities.
In all, PHAXIAM Therapeuticsspent€0.00 Mil on financial activities for the
three
months ended in Sep. 2023.
PHAXIAM Therapeutics (XPAR:PHXM) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
PHAXIAM Therapeutics's issuance of stock for the
three
months ended in Sep. 2023 was €0.00 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
PHAXIAM Therapeutics's repurchase of stock for the
three
months ended in Sep. 2023 was €0.00 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
PHAXIAM Therapeutics's net issuance of debt for the
three
months ended in Sep. 2023 was €0.00 Mil.
PHAXIAM Therapeutics received€0.00 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
PHAXIAM Therapeutics's net issuance of preferred for the
three
months ended in Sep. 2023 was €0.00 Mil.
PHAXIAM Therapeutics paid€0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
PHAXIAM Therapeutics's cash flow for dividends for the
three
months ended in Sep. 2023 was €0.00 Mil.
PHAXIAM Therapeutics received€0.00 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
PHAXIAM Therapeutics's other financing for the
three
months ended in Sep. 2023 was €0.00 Mil.
PHAXIAM Therapeutics received€0.00 Mil on other financial activities.
PHAXIAM Therapeutics Cash Flow from Financing Related Terms
PHAXIAM Therapeutics Cash Flow from Financing Historical Data
* Premium members only.
The historical data trend for PHAXIAM Therapeutics's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PHAXIAM Therapeutics Cash Flow from Financing Chart
PHAXIAM Therapeutics Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
PHAXIAM Therapeutics's Cash from Financing for the fiscal year that ended in Dec. 2022 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of €0.00 Mil mean?
PHAXIAM Therapeutics (XPAR:PHXM) has a Cash Flow from Financing of €0.00 Mil as of Sep. 2023. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for PHAXIAM Therapeutics and its competitors.
Is PHAXIAM Therapeutics' Cash Flow from Financing too high?
PHAXIAM Therapeutics' current Cash Flow from Financing is €0.00 Mil. Overall, PHAXIAM Therapeutics has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does PHAXIAM Therapeutics' Cash Flow from Financing compare to VRTX and REGN?
PHAXIAM Therapeutics' Cash Flow from Financing of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Biotechnology company?
A good Cash Flow from Financing depends on the Biotechnology industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for PHAXIAM Therapeutics and its competitors. PHAXIAM Therapeutics's current Cash Flow from Financing is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PHAXIAM Therapeutics stock overvalued right now?
PHAXIAM Therapeutics (XPAR:PHXM) has a current Cash Flow from Financing of €0.00 Mil. The current Cash Flow from Financing is €0.00 Mil. PHAXIAM Therapeutics' overall GF Score™ is 38/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For PHAXIAM Therapeutics (XPAR:PHXM), the current Cash Flow from Financing is €0.00 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PHAXIAM Therapeutics SA is a clinical-stage biopharmaceutical company developing therapies for severe forms of cancer and orphan diseases. Its platform uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, or RBC. It is developing a pipeline of product candidates for patients with high unmet medical needs. Its product candidate eryaspase, also referred to as GRASPA, targets the metabolism of cancer cells by depriving the cells of asparagine, an amino acid necessary for their survival and critical in maintaining the cells' rapid growth rate. The company is developing for the treatment of severe tumors, including pancreatic cancer, acute lymphoblastic leukemia, or ALL, and triple-negative breast cancer, or TNBC.
38GF Score
Get the complete analysis for XPAR:PHXM
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:PHXM has been successfully added to your 
